Recommendation Grading
A Directly based on meta-analysis of RCTs, Well-designed RCTs or diagnostic
studies performed on a population similar to the guideline's target population
B Directly based on RCTs or diagnostic studies with minor limitations;
overwhelmingly consistent evidence from observational studies
C Directly based on observational studies (case control and cohort design)
D Directly based on expert opinion, case reports, nonsystematic reviews.
LB Laboratory based
NR Not Rated
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies, at GuidelineCentral.com
Copyright © 2017 All rights reserved
AAAAIURT17012b
Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality
patient care. It focuses on the needs of primary care practice, but also is applicable to providers
at all levels. is Guideline should not be considered exclusive of other methods of care
reasonably directed at obtaining the same results. e ultimate judgment concerning the
propriety of any course of conduct must be made by the clinician aer consideration of each
individual patient situation. Neither IGC, the medical associations, nor the authors endorse
any product or service associated with the distributor of this clinical reference tool.
Source
Bernstein JA, Lang DM, Khan DA, et al. e diagnosis and management of acute and
chronic urticaria: 2014 update. J Allerg y Clin Immunol. 2014;133(5):1270-7.
Abbreviations
ACE, angiotensin-converting enzyme; APST, autologous plasma skin test; ASST,
autologous serum skin test; BUN, blood urea nitrogen; CBC, complete blood count;
CIU, chronic idiopathic urticaria; Cr, creatinine; CU, chronic urticaria; CUA, chronic
urticaria and angioedema; DPUA, delayed pressure urticaria/angioedema; DRESS,
drug-related rash with eosinophilia and systemic symptoms; EIAn, exercise-induced
anaphylaxis; ESR, erythrocyte sedimentation rate; FMF, familial Mediterranean fever;
G6PD, glucose-6-phosphate dehydrogenase; HES, hypereosinophilic syndrome; HUVS,
hypocomplementemic urticarial vasculitis syndrome; Ig, immune globulin; hyper-IgD,
hyper-IgD syndrome with periodic fever; K, potassium; LFT, liver function test; MWS,
Muckle-Wells syndrome; NA, not available; NOMID, neonatal-onset multisystem
inflammatory disease, also known as chronic infantile neurologic, cutaneous and articular
syndrome; NSAID, nonsteroidal anti-inflammatory drug ; PAPA, pyogenic arthritis,
pyoderma gangrenosum and acne syndrome; PFAPA, periodic fevers with aphthous
stomatitis, pharyngitis and adenitis; PUPPS, pruritic urticarial papules and plaques of
pregnancy; RCT, randomized controlled trial; SLE, systemic lupus erythematosus; SM,
systemic mastocytosis; t1/2, half-life; t
max
, time of maximum concentration; TMEP,
telangiectasia macularis eruptiva perstans; TNF, tumor necrosis factor; TRAPS, TNF
receptor-associated fever syndrome; TSH, thyroid-stimulating hormone; UP, urticaria
pigmentosa
